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Abstract
Esophageal cancer is the eighth most common cancer in the world and has an extremely dismal prognosis, with a
5-year survival of less than 20%. Current treatment options are limited, and thus identifying new molecular targets
and pathways is critical to derive novel therapies. Worldwide, more than 90% of esophageal cancers are esopha-
geal squamous cell cancer (ESCC). Previously, we identified that Krüppel-like factor 5 (KLF5), a key transcriptional
regulator normally expressed in esophageal squamous epithelial cells, is lost in human ESCC. To examine the
effects of restoring KLF5 in ESCC, we transduced the human ESCC cell lines TE7 and TE15, both of which lack
KLF5 expression, with retrovirus to express KLF5 upon doxycycline induction. When KLF5 was induced, ESCC cells
demonstrated increased apoptosis and decreased viability, with up-regulation of the proapoptotic factor BAX.
Interestingly, c-Jun N-terminal kinase (JNK) signaling, an important upstream mediator of proapoptotic pathways
including BAX, was also activated following KLF5 induction. KLF5 activation of JNK signaling was mediated by
KLF5 transactivation of two key upstream regulators of the JNK pathway, ASK1 and MKK4, and inhibition of
JNK blocked apoptosis and normalized cell survival following KLF5 induction. Thus, restoring KLF5 in ESCC cells
promotes apoptosis and decreases cell survival in a JNK-dependent manner, providing a potential therapeutic
target for human ESCC.
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Introduction
Esophageal cancer is the eighth most common cancer in the world,
with more than 480,000 new cases annually, and is responsible for
more than 400,000 deaths, making esophageal cancer the sixth most
common cause of cancer death [1]. Worldwide, more than 90% of
esophageal cancers are esophageal squamous cell cancer (ESCC) [2].
Despite improvements in surgical therapy, ESCC still has a 5-year
survival rate below 20% [2,3]. Neoadjuvant chemotherapy has been
proposed to improve survival rates in selected patients [4], but targeted
therapies for ESCC are still lacking. Potentially, these treatments could
be directed against factors and pathways involved in cell proliferation
and/or apoptosis, including targeting proapoptotic and antiapoptotic
factors and various cell cycle regulators [5]. However, many of these
factors, as well as the key epithelial transcriptional regulators underlying
these processes have not yet been delineated.
Krüppel-like factor 5 (KLF5) is a DNA-binding transcriptional regu-
lator highly expressed in epithelial cells, including in the proliferating
Abbreviations: ChIP, chromatin immunoprecipitation; ESCC, esophageal squamous cell
cancer; JNK, c-Jun N-terminal kinase; KLF5, Krüppel-like factor 5; MAP2K, mitogen-
activated protein kinase kinase; qPCR, quantitative real-time polymerase chain reaction
Address all correspondence to: Jonathan P. Katz, MD, Department of Medicine,
Gastroenterology Division, University of Pennsylvania Perelman School of Medicine,
913 Biomedical Research Building II/III, 421 Curie Boulevard, Philadelphia, PA 19104-
6144. E-mail: jpkatz@mail.med.upenn.edu
1This work was supported by National Institutes of Health (NIH), National Institute
of Diabetes and Digestive and Kidney Diseases (NIDDK) R01 DK080031 and
DK080031-02S1 to J.P.K., by the University of Pennsylvania Center for Molecular
Studies in Digestive and Liver Diseases (NIH, NIDDK P30 DK050306) through the
Molecular Pathology and Imaging Core, the Cell Culture Core, and the Molecular
Biology/Gene Expression Core, and by NIH, NIDDK P01 CA098101 (“Mechanisms
of Esophageal Carcinogenesis”).
2This article refers to supplementary materials, which are designated by Tables W1
and W2 and Figures W1 to W3 and are available online at www.neoplasia.com.
Received 16 December 2012; Revised 7 March 2013; Accepted 12 March 2013
Copyright © 2013 Neoplasia Press, Inc. All rights reserved 1522-8002/13/$25.00
DOI 10.1593/neo.122126
www.neoplasia.com
Volume 15 Number 5 May 2013 pp. 472–480 472
basal layer of the esophagus [6,7]. Within basal epithelial cells, KLF5
controls normal proliferation and migration, but KLF5 expression is
lost in ESCC [8–10]. In ESCC cells, KLF5 expression inhibits prolif-
eration, promotes apoptosis, and decreases invasion [11]. Interestingly,
KLF5 loss alone in the context of p53 mutation can transform primary
human esophageal keratinocytes, demonstrating an important function
for KLF5 in the development of human ESCC [9]. p53 mutation also
appears to be critical for the context-dependent role of KLF5 on pro-
liferation seen in esophageal and other epithelia [12,13]. KLF5 effects
on cell transformation and invasion appear to be mediated by direct
transcriptional regulation of the tumor suppressor NOTCH1 [9,14].
Yet, while the mechanisms of KLF5 function in ESCC proliferation
and invasion are beginning to be elucidated, less is understood about
the effects on apoptosis. Notably, KLF5 does not trigger apoptosis in
normal esophageal epithelial cells [12]. In ESCC cells, KLF5 induces
the proapoptotic factor BAX following UV irradiation, but the mecha-
nism of this induction is not known [11]. Since Klf5 overexpression has
few consequences in normal esophageal epithelia [7] and KLF5 appears
to be silenced epigenetically in at least a subset of ESCC [9], reactiva-
tion of KLF5 or otherwise restoring KLF5 is enticing as a therapeutic
approach for ESCC. In addition, KLF5 loss has been implicated in
several other cancers, including those of the breast and prostate [15,16],
and restoring KLF5 expression may therefore be beneficial in these
tumors as well.
The c-Jun N-terminal kinase ( JNK) pathway, a subgroup of
the mitogen-activated protein kinase (MAPK) superfamily, is an
important stress-induced proapoptotic pathway upstream of BAX
[17–19]. The MAPK kinases (MAP2Ks) MKK4 and MKK7 phos-
phorylate and activate JNK [17,20,21] and are a “bottleneck” for
JNK signaling [21]. In turn, MKK4 and MKK7 are activated by
ASK1, a MAPK kinase kinase (MAP3K) induced by various types
of cellular stress [22]. The response to JNK activation, however, is
influenced by the duration of activation, with short-term activation
leading to increased cell survival, while prolonged activation in-
duces proapoptotic pathways [23]. Thus, prolonged activation of
JNK in cancer, as by the up-regulation of key upstream regulators,
could be a valuable therapeutic approach [24]. As such, an under-
standing of the transcriptional regulation of these upstream kinases
is essential.
Here, we employ an inducible retroviral system to express KLF5
in human ESCC cells. We demonstrate that restoring KLF5 induces
apoptosis and diminishes cell survival in ESCC. Moreover, we define
JNK activation as critical for the proapoptotic function of KLF5
in ESCC.
Methods
Cell Culture
The human ESCC cell lines TE7 and TE15 [25,26] were cultured
at 37°C and 5% CO2 in Dulbecco’s modified Eagle’s medium/F12
media (Life Technologies, Grand Island, NY) supplemented with
5% BSA (Life Technologies), 100 units/ml penicillin, and 100 μg/ml
streptomycin (Life Technologies). For JNK inhibition, SP600125
(Enzo Life Sciences, Farmingdale, NY) was dissolved in DMSO, and
cells were treated at 10 μM for 0, 4, 8, and 24 hours. To block MKK4
phosphorylation, cells were treated for 5 hours with 50 μM PD98059
(Sigma-Aldrich, St Louis, MO), a potent MAP2K inhibitor [27,28],
solubilized in DMSO.
Viral Constructs and Infection
KLF5 cDNA was subcloned into the inducible pRevTre retroviral
vector (Clontech, Mountain View, CA). pRevTre and pRevTet-on
retroviral vectors were packaged by transfecting into AmphoPhoenix
cells (National Gene Vector Biorepository, Indianapolis, IN) using
Lipofectamine 2000 (Life Technologies) according to the manufac-
turer’s instructions. Virus-containing media were harvested 48 and
72 hours after transfection and filtered with a 0.45-μM MicroFunnel
Filter (Paul Life Sciences, Port Washington, NY), aliquoted, and
stored at −80°C until needed. TE7 and TE15 cells were infected with
culture supernatants from induced AmphoPhoenix cells at a 1:6
dilution. Cells were passaged for 24 hours and selected with 400 μg/ml
G418 (Life Technologies) and 3 μg/ml hygromycin (Mediatech Inc,
Manassas, VA) for 14 days. KLF5 was induced by treating cells with
4 μg/ml doxycycline.
RNA Analysis
RNA was extracted from ESCC cells using the RNeasy Mini Kit
(Qiagen, Valencia, CA), and cDNA was synthesized with Superscript
II Reverse Transcriptase (Life Technologies) following the manufac-
turer’s instructions. Quantitative real-time polymerase chain reaction
(qPCR) was carried out in triplicate on three samples for each experi-
mental condition using an ABI StepOne Plus (Life Technologies)
and SYBR Green PCR Master Mix (Life Technologies). TATA
box–binding protein was used as internal control. Primer sequences are
listed in Table W1.
Immunoblot Analysis
For each sample, 40 μg of total protein was separated on a NuPage
4% to 12% tris-acrylamide gel (Life Technologies) and transferred
onto a polyvinylidene difluoride membrane (EMDMillipore, Billercia,
MA), as described previously [8]. The membrane was blocked with
5% nonfat dry milk in tris-buffered saline with tween 20 (TBST) for
2 hours at room temperature and incubated overnight at 4°C with
1:10,000 rabbit anti-KLF5 [8] or 1:1000 dilution of anti–cleaved cas-
pase 3 (Cell Signaling Technology, Danvers, MA), anti–cleaved Poly
(ADP-ribose) polymerase (PARP; Cell Signaling Technology), anti–
phospho-JNK (Cell Signaling Technology), anti-JNK (Cell Signaling
Technology), anti-Ask1 (Cell Signaling Technology), anti–phospho-
MKK4 (Cell Signaling Technology), or anti-MKK4 (Cell Signaling
Technology). Membranes were then incubated for 1 hour at room
temperature with a 1:3000 dilution of anti-rabbit HRP (GEHealthcare
Life Sciences, Piscataway, NJ) and developed with ImmobilonWestern
Chemiluminescent HRP Substrate (EMD Millipore). Rabbit anti–
β-actin (Sigma-Aldrich) at 1:5000 served an internal control. Western
blots were representative of three separate experiments.
MTT Assay
Cell growth rate was evaluated by MTT assay as described pre-
viously [11]. In brief, 1 × 104 cells were seeded onto each well of a
48-well plate. After 24 hours, KLF5 was induced with doxycycline.
Medium was removed after an additional 24 and 48 hours, and cells
were washed in phosphate-buffered saline. MTT reagent (USB,
Cleveland, Ohio) was added at 2 mg/ml and incubated for 3 hours.
The dark blue crystals formed were dissolved in DMSO and the
absorbance measured at 570 nm with background subtracted at 650 nm
in a Beckman DU 600 spectrometer. Results represented the mean of
three separate experiments, each repeated in eight wells, and were
expressed as mean of absorbance relative to time zero.
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Annexin V Staining
Cells were plated onto four-well Lab-Tek chamber slides (Nunc,
Rochester, NY), and KLF5 was induced with doxycycline. At
24 hours after induction, cells were washed with phosphate-buffered
saline, and the Annexin V–FLUOS Staining Kit (Roche Applied
Biosciences, Indianapolis, IN) was used for the detection of apoptotic
cells as per the manufacturer’s instructions. Slides were mounted
with Prolong Gold with 4′,6-diamidino-2-phenylindole (DAPI)
mounting medium (Life Technologies), and images were captured
on a Nikon Eclipse E600 microscope (Nikon Instruments, Melville,
NY) with a Photometrics CoolSNAP charge-coupled device camera
(Roper Scientific, Tucson, AZ).
Luciferase Assay
Cells were induced with doxycycline and then transfected with
pGL3-Bax luciferase reporter (gift of Dr Moshe Oren, Weizman
Institute, Rehovot, Israel) [29] and pGL3-Bax-mut using Lipo-
fectamine 2000 (Life Technologies), as per the manufacturer’s instruc-
tions. pGL3-Bax-mut, containing a mutant KLF5 binding site, was
created using the Stratagene QuikChange Multi Site-Directed Muta-
genesis Kit (Agilent Technologies, Santa Clara, CA) by mutating the
sequence CCCCTCCCCT in pGL3-Bax to ATTTCTTTTC. Cells
were lysed with passive lysis buffer, and luciferase reporter activity
was analyzed with Dual-Luciferase Reporter Assay System (Promega,
Madison, WI) on a Glomax Multi-Detection Luminometer System
(Promega). Luciferase activity was normalized to renilla activity and
expressed as relative luciferase activity.
Chromatin Immunoprecipitation Assay
Chromatin immunoprecipitation (ChIP) assays were performed
with ChIP Assay Kit (EMD Millipore) according to the manufac-
turer’s instructions. Following KLF5 induction, cells were treated
with 1% formaldehyde for 10 minutes to cross-link associated pro-
tein to DNA. Cells were lysed with sodium dodecyl sulfate buffer
and sonicated with an Ultrasonic Processor (Sonics and Materials,
Newtown, CT) for four sets of 20-second pulses at 30% power. After
a 10-fold dilution, samples were precleared with protein A–agarose/
salmon sperm DNA for 30 minutes at 4°C and incubated overnight
at 4°C with 1:500 anti-KLF5 or 1:500 anti-rabbit IgG (Sigma-
Aldrich), as a negative control. Cells were then precipitated with pro-
tein A–agarose for 1 hour, heated at 65°C for 4 hours, and treated
with proteinase K. DNA was purified with the QiaQuick PCT
Purification Kit (Qiagen), and PCR was performed for BAX, ASK1,
and MKK4 using primers listed in Table W2. Putative binding sites
were identified using the Transcription Element Search System [30].
Densitometry Analysis
Immunoblots were scanned on a CanoScanLide 50 scanner (Canon
U.S.A., Lake Success, NY), and densitometry measurements of the
scanned bands were performed using the digitalized scientific software
program ImageJ (National Institutes of Health, Bethesda, MD). Data
were normalized to β-actin and expressed as means ± SEM.
Statistical Analysis
Data were analyzed for statistical significance with the Student’s
paired t test using Excel (Microsoft, Seattle, WA) and expressed as
means ± SEM. Values of P < .05 were considered statistically significant.
Results
KLF5 Decreases Viability and Induces Apoptosis in ESCC Cells
KLF5 expression is markedly decreased or absent in invasive
ESCC and in a majority of human ESCC cell lines [9]. We hypothe-
sized that loss of KLF5 was necessary for ESCC and that restoring
KLF5 would have a negative effect on ESCC cell survival. To eval-
uate the role of KLF5 in ESCC cell survival, we stably infected the
human ESCC cell lines TE7 and TE15, both of which have no detect-
able KLF5 expression [9], with doxycycline-inducible retroviral vectors
to express KLF5. By quantitative PCR (Figure 1A) and immunoblot
analyses (Figure 1B), we confirmed successful KLF5 expression follow-
ing doxycycline treatment. To examine cell viability following KLF5
induction, we performed MTT assays. KLF5-expressing cancer cells
showed a dramatic decrease in viability compared with controls [empty
vector (EV); Figure 1C]. Importantly, KLF5 expression triggers consid-
erable apoptosis in ESCC cells, as demonstrated by large increases in
annexin V staining (Figure W1) and marked elevation of cleaved PARP
[31] and cleaved caspase 3 [32], distinct executioners of the apoptotic
machinery (Figure 1D).
KLF5 Upregulates BAX Expression in ESCC Cells
To define the mechanisms of increased apoptosis by KLF5 in
ESCC, we focused initially on the proapoptotic Bcl-2 family mem-
ber BAX, which has been shown to be upregulated by stable expres-
sion of KLF5 in ESCC cells [11]. However, the mechanism of
BAX regulation by KLF5 is not known. Consistent with this, when
KLF5 was induced by doxycycline in TE7 and TE15 ESCC cells,
we observed marked induction of BAX, both at the RNA (Fig-
ure 2A) and protein (Figure 2B) levels. Using the Transcription
Element Search System [30], we identified a putative KLF5 bind-
ing site between −980 and −971 upstream of the BAX translational
start site. By ChIP assay, KLF5 bound to the 5′ regulatory region
of BAX within the region of the putative KLF5 binding site
(Figure 2C ). Luciferase reporter assays demonstrated BAX trans-
activation upon KLF5 induction in TE7 and TE15 cells, and this
activation was completely lost following mutation of the KLF5
binding site (Figure 2D).
KLF5 Activates JNK Signaling in ESCC Cells
JNK signaling, a subset of the MAPK pathway, triggers apopto-
sis in response to stress, reactive oxygen species, and other signals
[17–19]. We hypothesized that the JNK pathway is activated by
KLF5 in ESCC cells, contributing to the increased apoptosis fol-
lowing KLF5 induction in ESCC cells. In support of this, KLF5
induction increased phosphorylated JNK but did not alter levels
of total JNK in TE7 and TE15 cells (Figure 3A). Treatment of
cells with the small molecule, ATP-competitive JNK inhibitor
SP600125 [33,34] successfully blocked JNK phosphorylation
upon KLF5 induction (Figure 3B). These data suggested that KLF5
activated JNK signaling upstream of JNK and not by transcriptional
regulation of JNK.
To determine the role of KLF5-mediated JNK activation in ESCC
cells, we examined the impact of JNK inhibition on ESCC cell via-
bility and apoptosis following KLF5 induction. Interestingly, treat-
ment of TE7 and TE15 cells with SP600125 following KLF5
induction resulted in markedly elevated cell viability, compared to
cells with KLF5 induction alone (Figure 3C ); these effects were
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not seen with JNK inhibition alone, indicating that changes in cell
viability were not due to the inhibitor itself. JNK inhibition also
decreased apoptosis following KLF5 induction, as indicated by
reduced expression of cleaved PARP and cleaved caspase 3 (Fig-
ure 3D). Of note, changes in the expression of apoptotic markers
appeared to precede changes in cell viability; this may be due to
the time required for full activation of apoptotic pathways or to
limitations in the ability of the MTT assay to detect changes in cell
Figure 1. KLF5 decreases ESCC cell viability and induces apoptosis. (A) Stably infected TE7 and TE15 cells were treated with doxycycline
for 24 and 48 hours, leading to KLF5mRNA induction (*P < .001). (B) By Western blot, treatment of TE7 and TE15 cells with doxycycline
for 24 hours induced KLF5 protein. (C) By MTT assay, KLF5 induction with doxycycline for 24 or 48 hours decreased ESCC cell viability
(*P < .05; **P < .01). No significant changes in survival were seen with EV control. (D) Western blot demonstrated a marked increase in
the apoptotic markers cleaved (cl) caspase 3 and cleaved (cl) PARP following 24 hours of KLF5 induction.
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viability in real time. KLF5 induction also altered the expression of
several other apoptotic and survival factors (Figure W2), providing a
potential explanation for the failure of JNK inhibition to fully restore
ESCC cell viability following KLF5 induction, and KLF5 decreased
expression of the KLF family member KLF4, particularly relevant
since KLF5 and KLF4 may be yin-yang partners [35]. Nonetheless,
JNK activation by KLF5 upstream of BAX played an important role
in the apoptotic response.
Figure 2. KLF5 transactives BAX in human ESCC cells. (A) KLF5 induction with doxycycline for 24 and 48 hours in TE7 and TE15 ESCC
cell lines increased BAX mRNA (*P < .001). (B) KLF5 induction also increased BAX protein levels at 24 hours. (C) ChIP assays demon-
strated KLF5 binding to the 5′ regulatory region of BAX. IgG served as a negative control, and input DNA was a positive control. BAX ChIP
primers spanned the region from −1047 to −931 upstream of the translation start site and control primers spanned the region from
−952 to −785. (D) In ESCC cells, BAX promoter activity, assessed with a BAX-luciferase reporter, was increased four-fold by KLF5
following 24 hours of induction; mutation of the putative KLF5 binding site on BAX abolished this increase (*P < .01).
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Figure 3. KLF5 activates JNK signaling in ESCC. (A) By Western blot, phosphorylation of JNK increased five-fold to seven-fold in TE7 and
TE15 cells after KLF5 induction for 24 hours, while total JNK was unchanged. (B) Treatment of TE7 and TE15 cells with the small mol-
ecule JNK inhibitor SP600125 blocked JNK phosphorylation following KLF5 induction, as indicated by Western blot. (C) When TE7 and
TE15 were induced with doxycycline for 24 or 48 hours to express KLF5, treatment with JNK inhibitor inhibited the ability of KLF5 to
decrease cell viability, as assessed by MTT assay (*P < .05; **P < .001). (D) Treatment with JNK inhibitor also blocked the proapoptotic
effects of KLF5 in TE7 and TE15 cells, as demonstrated by levels of cleaved (cl) caspase 3 and cleaved (cl) PARP. KLF5 was induced for
the indicated times.
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KLF5 Regulates Upstream Mediators of JNK Signaling
Since JNK signaling is activated at the posttranslational level
[19,36], the mechanism of JNK activation by KLF5 is likely indirect.
Consistent with this, KLF5 upregulates phospho-JNK but not total
JNK. To identify the mechanism of JNK pathway regulation in
ESCC cells by KLF5, we examined levels of MKK4 and MKK7,
the predominant MAP2Ks upstream of JNK [37], and ASK1, a
MAP3K that can directly phosphorylate MKK4 and MKK7 [38].
Of note, different MAP3Ks predominate in the activation of MKKs
and JNK in response to various stimuli [18]. Interestingly, KLF5
induction in TE7 and TE15 cells resulted in increased expression of
both ASK1mRNA (Figure 4A) and protein (Figure 4B). To determine
Figure 4. KLF5 upregulates upstream mediators of the JNK pathway. (A and B) When KLF5 was induced for 24 hours in TE7 and TE15
ESCC cells, levels of ASK1 mRNA (A) and protein (B) increased. (C) ChIP assays demonstrated KLF5 binding to the 5′ regulatory region of
ASK1, in the vicinity of a predicted KLF5 binding site. IgG was a negative control, and input DNA served as a positive control. ASK1 ChIP
primers spanned the region from −502 to −280 upstream of the translation start site and control primers spanned the region from
−1833 to −1653. (D) By qPCR, KLF5 induction for 24 hours in ESCC cells resulted in a six-fold increase in MKK4 mRNA expression
as demonstrated by qPCR. (E) KLF5 bound to a region on MKK4 predicted to contain multiple KLF5 binding sites. IgG and input DNA
served as controls. Primers forMKK4 ChIP and control spanned the regions−226 to +4 and −1436 to −1266, respectively, upstream of
the translation start site. (F) As seen on Western blot, MKK phosphorylation was increased following KLF5 induction for 24 hours; this
increase was blocked by treatment with the MAP2K inhibitor PD98059. Note that total MKK4 is also increased by KLF5 induction,
indicative of both transcriptional and posttranslational regulation of MKK4.
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whetherASK1was a direct transcriptional target for KLF5, we examined
the 5′ regulatory region of ASK1 for putative KLF5 binding sites. We
identified a single putative KLF5 binding site from −449 to −437 up-
stream of the translation start site and, by ChIP assay, demonstrated
KLF5 binding to ASK1 in the vicinity of this putative binding site
(Figure 4C).
The ASK1 target MKK4 was also increased at both the mRNA
(Figure 4D) and protein levels (Figure 4E ) following KLF5 induc-
tion. However, no significant increase in MKK7 was observed upon
KLF5 induction (Figure W3), indicating the specificity for MKK4.
Surprisingly, by ChIP (Figure 4E ), KLF5 bound to the 5′ regulatory
region of MKK4 in an area from −126 to −72 predicted to have six
KLF5 binding sites. At the protein level, KLF5 induction increased
both total MKK4 and MKK4 phosphorylation (Figure 4F ), the for-
mer likely by direct transactivation of MKK4 and the latter through
ASK1 up-regulation. Consistent with this, treatment of cells with
PD98059, a small molecule inhibitor of MKK4 phosphorylation,
blocked MKK4 phosphorylation but did not affect total MKK4.
Discussion
The development and progression of cancers, including ESCC,
require several key steps including alteration in the control of cell
proliferation, survival, metastasis, and evasion of apoptosis [39].
Recently, we defined KLF5 loss as a key step in the development
of ESCC [9] and identified KLF5, through the cyclin-dependent
kinase inhibitor p21Waf1/Cip1, as an important brake on an aberrant
cell cycle [12]. The functions of KLF5 in these processes are generally
mediated by direct transcriptional regulation of its target genes, and
KLF5 may have both transactivating and repressive functions [40].
Here, we define a novel and important function for KLF5 in the
activation of JNK signaling to control ESCC cell viability and apop-
tosis. Of note, we have previously examined the effects of KLF5 on
apoptosis in ESCC cells and found similar consequences [11], and
subtle differences here may be due to inducible rather than constitu-
tive KLF5 expression.
Transcriptional control of multiple steps in the JNK pathway by
KLF5 is characteristic of a coherent feed-forward loop [41] and is
indicative of the critical role of KLF5 in the regulation of this signal-
ing network (Figure 5). When KLF5 is induced in ESCC cells, JNK
inhibition substantially restores but does not fully rescue cell via-
bility. These data suggest that, while JNK signaling is the major
mediator of cell viability and apoptosis induced by KLF5 in ESCC
cells, KLF5 transcriptional regulation of BAX and potentially other
genes may be functionally relevant. In fact, we find that a number
of other apoptotic and survival factors are also altered by KLF5 induc-
tion in ESCC cells. In addition, ASK1 and MKK4 can also activate
p38 MAPK [37,38], and PD98059 can also inhibit other MAP2Ks
[27]. As such, future studies will be directed toward understanding
the role of KLF5 in the activation of other MAPK pathways in
ESCC and in the transcriptional regulation of other proapoptotic and
antiapoptotic factors.
BAX is activated in response to multiple proapoptotic stimuli and
mediates apoptosis through the intrinsic pathway [42]. Proapoptotic
stimuli can also activate the JNK pathway, leading to phosphoryla-
tion of the BAX repressor 14-3-3, thereby liberating BAX to initiate
the apoptotic machinery [43,44]. While JNK signaling is often pro-
apoptotic, the function of JNK, like KLF5, can depend on context
[17,45]. p53 status is critical for determining KLF5 function [9,12],
and the antiapoptotic function of JNK may be related to p53 status
[46]. For example, JNK inhibition suppresses growth and induces
apoptosis of human tumor cells in a p53-dependent manner [47].
KLF5 does not trigger apoptosis in nontransformed esophageal epi-
thelial cells [12], and the differences of KLF5 function in these con-
texts could depend on p53 status as well. These context-dependent
functions of KLF5 and JNK on apoptosis merit further study.
In sum, we have defined a novel role for KLF5 in ESCC, an
extremely common cancer worldwide with a particularly poor prog-
nosis. Importantly, KLF5 overexpression does not produce dysplasia
or cancer in normal esophageal epithelia [7]. In ESCC, KLF5 expres-
sion is typically lost, and we demonstrate here that KLF5 inversely
affects ESCC cell survival in a JNK-dependent manner, although the
effects of KLF5 on apoptosis may be greater than can be attributed to
JNK activation alone. This suggests that loss of KLF5 may be nec-
essary for the development and progression of ESCC, and restoring
KLF5 function in ESCC may provide a novel therapeutic approach
for this deadly cancer. Future investigations will be directed toward
fully defining the factors and pathways downstream of KLF5 to bet-
ter delineate the molecular mechanisms underlying the pathogenesis
of ESCC.
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Table W1. Primer Sequences for qPCR.
Gene Forward Primer (5′ to 3′) Reverse Primer (5′ to 3′)
TATA box–binding protein TGTACCGCAGCTGCAAAAT GGATTATATTCAGCGTTTCG
KLF5 ACCCTGGTTGCACAAAAGTT CAGCCTTCCCCAGGTACACTT
BAX ACTTTGCCAGCAAACTGGTG GGAGGAAGTCCAATGTCCAG
ASK1 CCTAGCCAATGACCACATGA GACCAGGAAATCCATCCAAA
MKK4 TGGAGAAATTGGACGAGGAG GGCAATCACTACTCCGCATT
MKK7 GTCCTCCCTGGAACAGAAGC GGGAGCTCTCTGAGGATGG
TP53 AGGCCTTGGAACTCAAGGAT TTATGGCGGGAGGTAGACTG
TP73 CACCTCCCAAGGGTTACAGA GTACTGCTCGGGGATCTTCA
14-3-3 AGAAAGTGGAGTCCGAGCTG CCGGAAGTAATCACCCTTCA
BCL2 GCCCTGTGGATGACTGAGTA GGCCGTACAGTTCCACAAAG
MDM2 GGTGCTGTAACCACCTCACA TTTTTGTGCACCAACAGACTTT
NOXA CACGCTGCCATCGACTAC CCGACGCCACATTGTGTA
PUMA GACGACCTCAACGCACAGTA AGGAGTCCCATGATGAGATTGT
DR5 CCCACAACAAAAGAGGTCCA CCTGTCCATATTTGCAGGAGA
GADD45A GAGCTCCTGCTCTTGGAGAC GCAGGATCCTTCCATTGAGA
BIRC5 GGACCACCGCATCTCTACAT GTCTGGCTCGTTCTCAGTGG
KLF4 TTGCAGAGCTCAACAGGATG ATCAGCCACGGATACCTGAA
Table W2. ChIP Primer Sequences.
Name Forward Primer (5′ to 3′) Reverse Primer (5′ to 3′)
BAX-ChIP ACCCATGTAAACACCATTCAGA GGCAGAAACTAATCTGTGCTGA
BAX-CR (control) CCTGCTGATCTATCAGCACAG GCTGGTCTCTGAACTCCCAGA
ASK1-CHIP CAGCCCGCTCGTAAGGTG GGACGGAGCTTCCTTTTCTT
ASK1-CR (control) CCCCCTCCCGTCTCTACTAA TGAGACGGAGTTTCGCTCTT
MKK4-ChIP CAGCTGTCTGCTTCACAGGT GCCATTGTTGGGAGTGAAG
MKK4-CR (control) ATGCCCTAGGAGCAACAAGA GGCAAATTGAAGGTGAGAGC
Figure W1. After 24 hours of KLF5 induction, TE7 and TE15 cells demonstrated increased apoptosis, as indicated by annexin V staining
(green), compared to EV and uninduced controls. Note the lack of necrotic cells, which stain with propidium iodide (red). Cells were
counterstained with DAPI (blue). Original magnification, ×400.
Figure W2. KLF5 induction in TE15 cells altered mRNA expression of a broad array of apoptotic and survival factors, as assessed by
qPCR. Nontransformed primary human esophageal keratinocytes (EPC-T cells) were included for comparison.
Figure W3. Induction of KLF5 for 24 hours in TE7 and TE15 ESCC
cells did not alter the expression of MKK7 mRNA, as assessed by
qPCR, demonstrating the specificity of KLF5 for MKK4.
